< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
41 - 50 of 110
- Naar een gepersonaliseerde anti-darmkankertherapie door het targeten van de kankercelstofwisseling heterogeniteitFrom1 Oct 2016 → 12 Apr 2017Funding: FWO fellowships
- Endothelial cell metabolism blockade to induce tumor vessel normalization and improve immunotherapyFrom29 Sep 2016 → 6 May 2021Funding: FWO Strategic Basic Research Grant, BOF - Doctoral projects
- In silico identification of novel metabolic anti-angiogenic targets via public data mining and genome-scale metabolic modeling.From22 Aug 2016 → 29 Oct 2019Funding: Private funding of national origin - undefined
- Translating fundamental insights in endothelial metabolism: PFKFB3 drug discovery and developmentFrom1 Aug 2016 → 31 Jan 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- BIOMEX: a software to alleviate the bottlenecks in the analysis-to-interpretation pipeline of omics datasetsFrom27 Jun 2016 → 19 Jan 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- The unsuspected role of gluconeogenesis in endothelial cells and angiogenesis.From1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Is there a role for peroxisomal fatty acid beta-oxidation in vessel sprouting?From1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Endothelial mitochondria: enigmatic function and potential target for tumor anti-angiogenesis?From1 Oct 2015 → 30 Apr 2016Funding: FWO fellowships
- Glycogen: secret sugar reserves for sprouting vessels?From1 Oct 2015 → 30 Sep 2018Funding: FWO fellowships
- Do endothelial cells synthesize glucose and glycolytic intermediates to enable vessel sprouting in avascular (glucose-deprived) regions?From1 Oct 2015 → 1 Jul 2017Funding: FWO fellowships
Publications
1 - 10 of 587
- Fatty acid oxidation fuels natural killer cell responses against infection and cancer.(2024)
Authors: Peter Carmeliet
Pages: e231925412 - Targeting hypoxia-inducible factors: therapeutic opportunities and challenges(2024)
Authors: Peter Carmeliet
- Editorial Expression of Concern: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system.(2024)
Authors: Peter Carmeliet
Pages: E12 - The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression (vol 23, pg 1476, 2018)(2023)
Authors: Peter Carmeliet
- Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice(2023)
Authors: Anh-Co Truong, Koen Veys, Mieke Dewerchin, Peter Carmeliet
- Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells(2023)
Authors: Peter Carmeliet
Pages: 1446 - 1459 - Renal Endothelial Cell Metabolism in Health and Acute Kidney Injury: a window for therapeutic opportunities(2023)
Authors: Mila Borri, Peter Carmeliet, Guy Eelen, Sébastien Dumas
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway(2023)
Authors: Mieke Dewerchin, Peter Carmeliet
- PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS(2023)
Authors: Peter Carmeliet
- Understanding tumour endothelial cell heterogeneity and function from single-cell omics(2023)
Authors: Peter Carmeliet
Pages: 544 - 564
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)